All In Biotech

Drug Trial Radar · NCT07221474

A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of V940 in Combination With Pembrolizumab and Chemotherapy as First-Line Treatment for Participants With Metastatic Squamous NSCLC (INTerpath-013)

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Dec 12, 2025

Primary completion

Jul 2, 2029

Study completion May 6, 2031

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
Collaborators
ModernaTX, Inc.
First posted
Oct 28, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers want to know if intismeran autogene (the study treatment) given with pembrolizumab and chemotherapy can treat metastatic treatment-naive squamous non-small cell lung cancer (NSCLC). Intismeran autogene is designed to help a person's immune system attack their specific cancer. The goal of this study is to learn if people who receive intismeran autogene with pembrolizumab and chemotherapy live longer overall and without the cancer growing or spreading compared to people who receive placebo with pembrolizumab and chemotherapy. A placebo looks like the study treatment but has no study treatment in it. Using a placebo helps researchers better understand the effects of the study treatment.

Conditions

  • Squamous Non-small Cell Lung Cancer

Interventions

  • Intismeran AutogeneBiological

    1 mg Intramuscular (IM) Injection

  • PembrolizumabBiological

    200 mg IV Infusion

  • CarboplatinDrug

    Area Under the Curve (AUC) either 6 or 5 (mg/mL/min) IV Infusion

  • PaclitaxelDrug

    200 or 175 mg/m\^2 IV Infusion

  • Nab-paclitaxelDrug

    100 mg/m\^2 IV Infusion

  • PlaceboOther

    Placebo matched to Intismeran Autogene IM injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: Up to ~32 months
  2. Overall Survival (OS)Time frame: Up to ~42 months

Locations

56 sites in 11 countries. Site status is shown where the registry gives one.

  • Moffitt Cancer Center ( Site 0021)

    Tampa, Florida · Recruiting

  • VA Ann Arbor Healthcare System ( Site 0019)

    Ann Arbor, Michigan · Recruiting

  • Washington University School of Medicine ( Site 0024)

    St Louis, Missouri · Recruiting

  • Valley Health Systems - Ridgewood Campus ( Site 0010)

    Paramus, New Jersey · Recruiting

  • New York Oncology Hematology (NYOH) - Albany Medical Center ( Site 9001)

    Albany, New York · Recruiting

  • Cleveland Clinic - Ohio ( Site 0016)

    Cleveland, Ohio · Recruiting

  • Good Samaritan Regional Medical Center-Samaritan Pastega Regional Cancer Center ( Site 0025)

    Corvallis, Oregon · Recruiting

  • Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 9000)

    Nashville, Tennessee · Recruiting

  • Texas Oncology - Central/South Texas ( Site 8002)

    Austin, Texas · Recruiting

  • Virginia Cancer Specialists ( Site 0003)

    Fairfax, Virginia · Recruiting

  • Swedish Medical Center-Swedish Cancer Institute ( Site 0023)

    Seattle, Washington · Recruiting

  • Instituto Alexander Fleming ( Site 0201)

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina · Recruiting

  • Hospital Italiano de Buenos Aires ( Site 0200)

    Ciudad Autonoma de Buenos Aires., Buenos Aires, Argentina · Recruiting

  • Instituto de Investigaciones Clínicas Mar del Plata ( Site 0205)

    Mar del Plata, Buenos Aires, Argentina · Recruiting

  • Clinica Adventista Belgrano ( Site 0206)

    Caba., Buenos Aires F.D., Argentina · Recruiting

  • Fundacion Estudios Clinicos ( Site 0207)

    Rosario, Santa Fe Province, Argentina · Recruiting

  • Sanatorio Parque ( Site 0203)

    Rosario, Santa Fe Province, Argentina · Recruiting

  • Westmead Hospital ( Site 0400)

    Westmead, New South Wales, Australia · Recruiting

  • Princess Alexandra Hospital ( Site 0403)

    Woolloongabba, Queensland, Australia · Recruiting

  • One Clinical Research ( Site 0402)

    Nedlands, Western Australia, Australia · Recruiting

  • Bradford Hill Norte ( Site 0308)

    Antofagasta, Chile · Recruiting

  • Centro de Estudios Clínicos SAGA ( Site 0307)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Fundación Arturo López Pérez ( Site 0300)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Bradfordhill ( Site 0301)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Centre Georges François Leclerc ( Site 0805)

    Dijon, Cote-d Or, France · Recruiting

  • Institut de Cancérologie de l'Ouest ( Site 0801)

    Angers, Pays de la Loire Region, France · Recruiting

  • CHU GABRIEL MONTPIED ( Site 0802)

    Clermont-Ferrand, Puy-de-Dome, France · Recruiting

  • Ospedale San Raffaele-Oncologia Medica ( Site 1002)

    Milan, Italy · Recruiting

  • Fondazione IRCCS Istituto Nazionale Dei Tumori ( Site 1000)

    Milan, Italy · Recruiting

  • AO Santa Maria della Misericordia-Oncology Department ( Site 1005)

    Perugia, Italy · Recruiting

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 1001)

    Roma, Italy · Recruiting

  • Ospedale Santa Maria delle Croci-Dipartimento Oncoematologico ( Site 1004)

    Ravenna, Emilia-Romagna, Italy · Recruiting

  • Wielkopolskie Centrum Pulmonologii i Torakochirurgii ( Site 1101)

    Poznan, Greater Poland Voivodeship, Poland · Recruiting

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 1100)

    Warsaw, Masovian Voivodeship, Poland · Recruiting

  • Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 1102)

    Przemyśl, Podkarpackie Voivodeship, Poland · Recruiting

  • Asan Medical Center ( Site 0503)

    Seoul, South Korea · Recruiting

  • Samsung Medical Center ( Site 0502)

    Seoul, South Korea · Recruiting

  • National Cancer Center ( Site 0504)

    Goyang-si, Kyonggi-do, South Korea · Recruiting

  • Seoul National University Bundang Hospital ( Site 0500)

    Seongnam-si, Kyonggi-do, South Korea · Recruiting

  • Chungbuk National University Hospital-Internal medicine ( Site 0501)

    Cheongju-si, North Chungcheong, South Korea · Recruiting

Showing 40 of 56 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.